Publish Date
30 Nov -0001
<![CDATA[Background: Ischemic stroke has become one of the most life-threatening diseases with high disability and mortality rates. New treatment strategies with neuroprotective functions are urgently needed to treat it. Icariin is a flavonol glycoside that has antioxidant capacity, promote neurite outgrowth and modulate the immune system. This systematic review was conducted to assess and evaluate the efficacy, safety and feasibility of icariin in the treatment of ischemic stroke.Methods: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020. We included predefined inclusion criteria, including: original articles published in the last 10 years and in English. Abstracts, preprints, reviews, articles not published in English and inaccessible full-text articles are excluded. Data extracted from PubMed and ScienceDirect databases using keywords "ischemic stroke“ or ‘”cerebral ischemic-reperfusion injury“ and '"icariin". The JBI critical appraisal tool was used to assess the quality of the data.Results: From the data obtained, a total of 7 research data were found eligible to review. The results showed that icariin had positive effects in reducing the levels of pro-inflammatory cytokines such as interleukin-1beta (IL-1beta), IL-6, and tumour necrosis factor-alfa (TNF-alfa) as well as maintaining brain cell viability. In addition, icariin either given alone or in combination improves post-ischemic neurological function and reduces infarct volume.Conclusion: Icariin has demonstrated neuroprotective effects necessary for neuroprotection and neurovascular recovery. In vitro and in vivo studies using Icariin alone or in combination with other modalities have also shown enhanced protection.]]>
Copyrights © 0000
